Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness and Safety of YM-101 Eye Drops in Dry Eye Syndrome
NCT06792903Phase 1Completed
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Apr 2024
- Primary completion
- May 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YM-101 in dry eye syndrome (DED) (3 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Corneal Staining Score at 4 weeks, Systemic Adverse Events at 12 weeks and 5 more. Started Apr 2024; status: completed.
02
Drugs
YM-101
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT06792903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792903.